ESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?

Utilisation of the ESMO-MCBS in practice of HTA.

1Ludwig Boltzmann Institute of Health technology Assessment, Vienna), Austria; 2Independent Pharmaceutical Consultant, Mellieha, Malta; 3Department of Finance, University of Austria, Vienna, Austria; 4Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia; 5Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow,UK; 6Depa...

Health Technology Assessment - HTA

US drug marketing: how does promotion correspond with health value?

The pharmaceutical industry uses a variety of techniques to promote its products to clinicians, including gifts and free food, advertisements, and detailing by company representatives. Although manufacturers might argue that drug promotion supports physician education, which in turn leads to more informed prescribing, studies have shown that greater contact with drug sales representatives is as...

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA)

BACKGROUND "Patient-Reported Outcome" (PRO) is used as an umbrella term for different concepts for measuring subjectively perceived health status e. g. as treatment effects. Their common characteristic is, that the appraisal of the health status is reported by the patient himself. In order to describe the informative value of PRO in Health Technology Assessment (HTA) first an overview of concep...

Agency for Health Technology Assessment Guidelines for conducting Health Technology Assessment (HTA)